The CDSCO has approved TLC's new drug application (NDA) of Amphotericin B Liposome for Injection 50 mg in India for immediate importation per approved usage and indication.
Under the terms of the agreement, TLC is eligible to receive up to US$25 million in upfront payments for each product and subsequent regulatory and sales milestone payments.